Investor Presentaiton

IBI-188 (Letaplimab): Potential Best-in-Class anti-CD47 Monoclonal Antibody IBI-188 Differentiated Advantages Optimized affinity for balanced toxicity and efficacy Stronger efficacy than hu5F9 and comparable tolerability in NHPS Pre-clinical Highlights IBI188 in Raji on NOD/SCID model Clinical Highlights Phase 1a data published on SITC 2020: Well tolerated. Completed all pre-specified seven dosage without any DLT (maximum dose 30mg/kg QW). Good safety profile. TRAE mostly grade 1-2. 15% Anemia at controllable level. Anti-tumor activity observed in 1a. IBI-188 Development Program Overview China Completed Phase 1a dosage escalation and finalizing Phase 1a, started Phase 1b for both MDS and AML in 2H 2020 Tumor volume (mm³) 1750 1500- 1250- 1000- 750- 500- 250- 0 8 11 13 16 20 23 27 30 34 Days post tumor implantation Clinical vehicle US h-IgG, 0.5 mg/kg IBI188, 0.02mg/kg IBI188, 0.1mg/kg progress IBI188, 0.5mg/kg Completed Phase 1a dosage escalation and started Phase 1b in MDS in 1H 2020 Published Phase 1a data in SITC in Nov 2020 2021 plan Plan to start Phase 3 or pivotal trial in China in MDS in 2021 Proven well tolerability and good safety in 63 pts dosed in Phase 1a. Proven efficacy in 30 pts in 1L MDS study. Global development ongoing; China to enter Phase 3 or pivotal trial for 1L MDS in 2021. Innovent Confidential Copyright©2021 Innovent Biologics 24

View entire presentation